Tumor microenvironment and cancer therapy resistance

Cancer Letters

Volumn 380, Issue 1, 2016, Pages 205-215

  Sun, Yu ^a,b,c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b VA Seattle Medical Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Acquired resistance; Cancer therapy; Personalized medicine; Tumor microenvironment

Indexed keywords

AFLIBERCEPT; ALDESLEUKIN; ALPHA2B INTERFERON; AXITINIB; BEVACIZUMAB; CABOZANTINIB; CHLORMETHINE; CLAZAKIZUMAB; CYTARABINE; DAUNORUBICIN; DEMCIZUMAB; DOXORUBICIN; ENOTICUMAB; FLUOROURACIL; FOLIC ACID ANTAGONIST; IPILIMUMAB; NESVACUMAB; NIVOLUMAB; OLOKIZUMAB; PACLITAXEL; PARSATUZUMAB; PAZOPANIB; PEMBROLIZUMAB; SIPULEUCEL T; SONIDEGIB; SORAFENIB; SUNITINIB; TREBANANIB; UNINDEXED DRUG; VANDETANIB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

BREAST CANCER; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL DIFFERENTIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; EPIGENETICS; EXOSOME; EXTRACELLULAR MATRIX; GENE MUTATION; GENOTOXICITY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LEUKEMIA; LYMPHOMA; NONHUMAN; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SHORT SURVEY; SOLID TUMOR; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; VASCULARIZATION; ANIMAL; DISEASE COURSE; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PRECISION MEDICINE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84939144106     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.07.044     Document Type: Review

References (106)

1. [1] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
2. [2] Balkwill, F., Mantovani, A., Inflammation and cancer: back to Virchow?. Lancet 357 (2001), 539–545.
3. [3] Paget, S., The distribution of secondary growths in cancer of the breast. Lancet 133 (1889), 571–573.
4. [4] Chen, F., Zhuang, X., Lin, L., Yu, P., Wang, Y., Shi, Y., et al. New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med, 13, 2015, 278.
5. [5] Junttila, M.R., de Sauvage, F.J., Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501 (2013), 346–354.
6. [6] Sun, Y., Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures. Med. Res. Rev 35 (2015), 408–436.
7. [7] Quail, D.F., Joyce, J.A., Microenvironmental regulation of tumor progression and metastasis. Nat. Med 19 (2013), 1423–1437.
8. [8] Song, T., Dou, C., Jia, Y., Tu, K., Zheng, X., TIMP-1 activated carcinoma-associated fibroblasts inhibit tumor apoptosis by activating SDF1/CXCR4 signaling in hepatocellular carcinoma. Oncotarget 6 (2015), 12061–12079.
9. [9] Tanaka, K., Miyata, H., Sugimura, K., Fukuda, S., Kanemura, T., Yamashita, K., et al. miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts. Carcinogenesis 36 (2015), 894–903.
10. [10] Ozdemir, B.C., Pentcheva-Hoang, T., Carstens, J.L., Zheng, X., Wu, C.C., Simpson, T.R., et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25 (2014), 719–734.
11. [11] Rhim, A.D., Oberstein, P.E., Thomas, D.H., Mirek, E.T., Palermo, C.F., Sastra, S.A., et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25 (2014), 735–747.
12. [12] Duluc, C., Moatassim-Billah, S., Chalabi-Dchar, M., Perraud, A., Samain, R., Breibach, F., et al. Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. EMBO Mol. Med 7 (2015), 735–753.
13. [13] Erez, N., Truitt, M., Olson, P., Arron, S.T., Hanahan, D., Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 17 (2010), 135–147.
14. [14] Erez, N., Glanz, S., Raz, Y., Avivi, C., Barshack, I., Cancer associated fibroblasts express pro-inflammatory factors in human breast and ovarian tumors. Biochem. Biophys. Res. Commun 437 (2013), 397–402.
15. [15] Nagasaki, T., Hara, M., Nakanishi, H., Takahashi, H., Sato, M., Takeyama, H., Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Br. J. Cancer 110 (2014), 469–478.
16. [16] Zhang, X.H., Jin, X., Malladi, S., Zou, Y., Wen, Y.H., Brogi, E., et al. Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell 154 (2013), 1060–1073.
17. [17] Yuan, J., Liu, M., Yang, L., Tu, G., Zhu, Q., Chen, M., et al. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and beta1-integrin signaling pathway in tumor cells. Breast Cancer Res, 17, 2015, 69.
18. [18] Peiris-Pages, M., Sotgia, F., Lisanti, M.P., Chemotherapy induces the cancer-associated fibroblast phenotype, activating paracrine Hedgehog-GLI signalling in breast cancer cells. Oncotarget 6 (2015), 10728–10745.
19. [19] Weis, S.M., Cheresh, D.A., Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med 17 (2011), 1359–1370.
20. [20] Semenza, G.L., Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene 32 (2013), 4057–4063.
21. [21] Tredan, O., Galmarini, C.M., Patel, K., Tannock, I.F., Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst 99 (2007), 1441–1454.
22. [22] Yuan, M.M., Xu, Y.Y., Chen, L., Li, X.Y., Qin, J., Shen, Y., TLR3 expression correlates with apoptosis, proliferation and angiogenesis in hepatocellular carcinoma and predicts prognosis. BMC Cancer, 15, 2015, 245.
23. [23] Ariotti, C., Wagner, V.P., Salvadori, G., Carrard, V.C., Martins, M.A., Filho, J.J., et al. VEGFR1 and VEGFR2 in lip carcinogenesis and its association with microvessel density. Tumour Biol, 2015, 10.1007/s13277-015-3454-7.
24. [24] Lee, J.G., Wu, R., Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1 alpha in EGFR-mutated lung cancer in vitro and in vivo. Neoplasia 17 (2015), 190–200.
25. [25] Hegde, P.S., Jubb, A.M., Chen, D., Li, N.F., Meng, Y.G., Bernaards, C., et al. Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin. Cancer Res 19 (2013), 929–937.
26. [26] Yamada, K., Maishi, N., Akiyama, K., Towfik, A.M., Ohga, N., Kawamoto, T., et al. CXCL12-CXCR7 axis is important for tumor endothelial cell angiogenic property. Int. J. Cancer, 2015, 10.1002/ijc.29655.
27. [27] Flaherty, K.T., Manola, J.B., Pins, M., McDermott, D.F., Atkins, M.B., Dutcher, J.J., et al. BEST: a randomized phase II study of vascular endothelial growth factor, RAF kinase, and mammalian target of rapamycin combination targeted therapy with Bevacizumab, Sorafenib, and Temsirolimus in advanced renal cell carcinoma-A trial of the ECOG-ACRIN Cancer Research Group (E2804). J. Clin. Oncol 33 (2015), 2384–2391.
28. [28] Martino, M.M., Briquez, P.S., Guc, E., Tortelli, F., Kilarski, W.W., Metzger, S., et al. Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing. Science 343 (2014), 885–888.
29. [29] Klemm, F., Joyce, J.A., Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol 25 (2015), 198–213.
30. [30] Friedl, P., Alexander, S., Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 147 (2011), 992–1009.
31. [31] Weaver, V.M., Lelievre, S., Lakins, J.N., Chrenek, M.A., Jones, J.C., Giancotti, F., et al. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2 (2002), 205–216.
32. [32] Goel, H.L., Sayeed, A., Breen, M., Zarif, M.J., Garlick, D.S., Leav, I., et al. beta1 integrins mediate resistance to ionizing radiation in vivo by inhibiting c-Jun amino terminal kinase 1. J. Cell. Physiol 228 (2013), 1601–1609.
33. [33] Seguin, L., Kato, S., Franovic, A., Camargo, M.F., Lesperance, J., Elliott, K.C., et al. An integrin beta(3)-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat. Cell Biol 16 (2014), 457–468.
34. [34] Levental, K.R., Yu, H.M., Kass, L., Lakins, J.N., Egeblad, M., Erler, J.T., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139 (2009), 891–906.
35. [35] Olive, K.P., Jacobetz, M.A., Davidson, C.J., Gopinathan, A., McIntyre, D., Honess, D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324 (2009), 1457–1461.
36. [36] Bergamaschi, A., Tagliabue, E., Sorlie, T., Naurne, B., Triulzi, T., Orlandi, R., et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J. Pathol 214 (2008), 357–367.
37. [37] Naba, A., Clauser, K.R., Hoersch, S., Liu, H., Carr, S.A., Hynes, R.O., The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol. Cell. Proteomics, 11, 2012 M111.014647.
38. [38] Gomes, L.R., Vessoni, A.T., Menck, C.F., Three-dimensional microenvironment confers enhanced sensitivity to doxorubicin by reducing p53-dependent induction of autophagy. Oncogene, 2015, 10.1038/onc.2014.461.
39. [39] Feng, M.X., Ma, M.Z., Fu, Y., Li, J., Wang, T., Xue, F., et al. Elevated autocrine EDIL3 protects hepatocellular carcinoma from anoikis through RGD-mediated integrin activation. Mol. Cancer, 13, 2014, 226.
40. [40] Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12 (2012), 252–264.
41. [41] Shojaei, F., Wu, X., Qu, X., Kowanetz, M., Yu, L., Tan, M., et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 6742–6747.
42. [42] Bayne, L.J., Beatty, G.L., Jhala, N., Clark, C.E., Rhim, A.D., Stanger, B.Z., et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21 (2012), 822–835.
43. [43] Motz, G.T., Coukos, G., The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol 11 (2011), 702–711.
44. [44] Komohara, Y., Morita, T., Annan, D.A., Horlad, H., Ohnishi, K., Yamada, S., et al. The coordinated actions of TIM-3 on cancer and myeloid cells in the regulation of tumorigenicity and clinical prognosis in clear cell renal cell carcinomas. Cancer Immunol. Res, 2015, 10.1158/2326-6066.CIR-14-0156.
45. [45] Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med 14 (2008), 518–527.
46. [46] Weizman, N., Krelin, Y., Shabtay-Orbach, A., Amit, M., Binenbaum, Y., Wong, R.J., et al. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. Oncogene 33 (2014), 3812–3819.
47. [47] Yang, C., He, L., He, P., Liu, Y., Wang, W., He, Y., et al. Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway. Med. Oncol, 32, 2015, 352.
48. [48] Wan, S., Zhao, E., Kryczek, I., Vatan, L., Sadovskaya, A., Ludema, G., et al. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology 147 (2014), 1393–1404.
49. [49] Ruffell, B., Coussens, L.M., Macrophages and therapeutic resistance in cancer. Cancer Cell 27 (2015), 462–472.
50. [50] Hossain, F., Al-Khami, A.A., Wyczechowska, D., Hernandez, C., Zheng, L., Reiss, K., et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol. Res, 2015, 10.1158/2326-6066.CIR-15-0036.
51. [51] Simons, M., Raposo, G., Exosomes – vesicular carriers for intercellular communication. Curr. Opin. Cell Biol 21 (2009), 575–581.
52. [52] Schageman, J., Zeringer, E., Li, M., Barta, T., Lea, K., Gu, J., et al. The complete exosome workflow solution: from isolation to characterization of RNA cargo. Biomed. Res. Int, 2013, 2013, 253957.
53. [53] Peinado, H., Aleckovic, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med 18 (2012), 883–891.
54. [54] Aung, T., Chapuy, B., Vogel, D., Wenzel, D., Oppermann, M., Lahmann, M., et al. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 15336–15341.
55. [55] Ciravolo, V., Huber, V., Ghedini, G.C., Venturelli, E., Bianchi, F., Campiglio, M., et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J. Cell. Physiol 227 (2012), 658–667.
56. [56] Luga, V., Zhang, L., Viloria-Petit, A.M., Ogunjimi, A.A., Inanlou, M.R., Chiu, E., et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell 151 (2012), 1542–1556.
57. [57] Boelens, M.C., Wu, T.J., Nabet, B.Y., Xu, B., Qiu, Y., Yoon, T., et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell 159 (2014), 499–513.
58. [58] Lugini, L., Cecchetti, S., Huber, V., Luciani, F., Macchia, G., Spadaro, F., et al. Immune surveillance properties of human NK cell-derived exosomes. J. Immunol 189 (2012), 2833–2842.
59. [59] Naslund, T., Gehrmann, U., Qazi, K., Karlsson, M., Gabrielsson, S., Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity. J. Immunol 190 (2013), 2712–2719.
60. [60] Challagundla, K.B., Wise, P.M., Neviani, P., Chava, H., Murtadha, M., Xu, T., et al. Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. J. Natl Cancer Inst, 107, 2015, 10.1093/jnci/djv135.
61. [61] Corcoran, C., Rani, S., O'Driscoll, L., miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Prostate 74 (2014), 1320–1334.
62. [62] Takahashi, R.U., Miyazaki, H., Ochiya, T., The roles of MicroRNAs in breast cancer. Cancers 7 (2015), 598–616.
63. [63] Obenauf, A.C., Zou, Y., Ji, A.L., Vanharanta, S., Shu, W., Shi, H., et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 520 (2015), 368–372.
64. [64] Chabner, B.A., Roberts, T.G. Jr., Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer 5 (2005), 65–72.
65. [65] Sun, Y., Nelson, P.S., Molecular pathways: involving microenvironment damage responses in cancer therapy resistance. Clin. Cancer Res 18 (2012), 4019–4025.
66. [66] Coppe, J.P., Patil, C.K., Rodier, F., Sun, Y., Munoz, D.P., Goldstein, J., et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6 (2008), 2853–2868.
67. [67] Kuilman, T., Peeper, D.S., Senescence-messaging secretome: SMS-ing cellular stress. Nat. Rev. Cancer 9 (2009), 81–94.
68. [68] Neves, J., Demaria, M., Campisi, J., Jasper, H., Of flies, mice, and men: evolutionarily conserved tissue damage responses and aging. Dev. Cell 32 (2015), 9–18.
69. [69] Kuilman, T., Michaloglou, C., Vredeveld, L.C., Douma, S., van Doorn, R., Desmet, C.J., et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133 (2008), 1019–1031.
70. [70] Acosta, J.C., O'Loghlen, A., Banito, A., Guijarro, M.V., Augert, A., Raguz, S., et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133 (2008), 1006–1018.
71. [71] Rodier, F., Coppe, J.P., Patil, C.K., Hoeijmakers, W.A., Munoz, D.P., Raza, S.R., et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol 11 (2009), 973–979.
72. [72] Rodier, F., Munoz, D.P., Teachenor, R., Chu, V., Le, O., Bhaumik, D., et al. DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. J. Cell Sci 124 (2011), 68–81.
73. [73] Sun, Y., Campisi, J., Higano, C., Beer, T.M., Porter, P., Coleman, I., et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat. Med 18 (2012), 1359–1368.
74. [74] Gilbert, L.A., Hemann, M.T., DNA damage-mediated induction of a chemoresistant niche. Cell 143 (2010), 355–366.
75. [75] Gilbert, L.A., Hemann, M.T., Chemotherapeutic resistance: surviving stressful situations. Cancer Res 71 (2011), 5062–5066.
76. [76] Roodhart, J.M.L., Daenen, L.G.M., Stigter, E.C.A., Prins, H.J., Gerrits, J., Houthuijzen, J.M., et al. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell 20 (2011), 370–383.
77. [77] Shaked, Y., Henke, E., Roodhart, J.M.L., Mancuso, P., Langenberg, M.H.G., Colleoni, M., et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14 (2008), 263–273.
78. [78] Duan, C.W., Shi, J., Chen, J., Wang, B., Yu, Y.H., Qin, X., et al. Leukemia propagating cells rebuild an evolving niche in response to therapy. Cancer Cell 25 (2014), 778–793.
79. [79] Kim, M., Koh, Y.J., Kim, K.E., Koh, B.I., Nam, D.H., Alitalo, K., et al. CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res 70 (2010), 10411–10421.
80. [80] Mannino, M., Chalmers, A.J., Radioresistance of glioma stem cells: intrinsic characteristic or property of the ‘microenvironment-stem cell unit’?. Mol. Oncol 5 (2011), 374–386.
81. [81] Zoni, E., van der Pluijm, G., Gray, P.C., Kruithof-de Julio, M., Epithelial plasticity in cancer: unmasking a MicroRNA network for TGF-beta-, Notch-, and Wnt-mediated EMT. J. Oncol, 2015, 2015, 198967.
82. [82] Cuiffo, B.G., Campagne, A., Bell, G.W., Lembo, A., Orso, F., Lien, E.C., et al. MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis. Cell Stem Cell 15 (2014), 762–774.
83. [83] Landsberg, J., Kohlmeyer, J., Renn, M., Bald, T., Rogava, M., Cron, M., et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 490 (2012), 412–416.
84. [84] Bhat, K.P., Balasubramaniyan, V., Vaillant, B., Ezhilarasan, R., Hummelink, K., Hollingsworth, F., et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell 24 (2013), 331–346.
85. [85] Dijkgraaf, E.M., Heusinkveld, M., Tummers, B., Vogelpoel, L.T., Goedemans, R., Jha, V., et al. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res 73 (2013), 2480–2492.
86. [86] Klug, F., Prakash, H., Huber, P.E., Seibel, T., Bender, N., Halama, N., et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24 (2013), 589–602.
87. [87] Tripathi, C., Tewari, B.N., Kanchan, R.K., Baghel, K.S., Nautiyal, N., Shrivastava, R., et al. Macrophages are recruited to hypoxic tumor areas and acquire a pro-angiogenic M2-polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin. Oncotarget 5 (2014), 5350–5368.
88. [88] Den, R.B., Yousefi, K., Trabulsi, E.J., Abdollah, F., Choeurng, V., Feng, F.Y., et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J. Clin. Oncol 33 (2015), 944–951.
89. [89] Sedelaar, J.P., Schalken, J.A., The need for a personalized approach for prostate cancer management. BMC Med, 13, 2015, 109.
90. [90] Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med 364 (2011), 2507–2516.
91. [91] Young, K., Minchom, A., Larkin, J., BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation. Future Oncol 8 (2012), 499–507.
92. [92] Meric-Bernstam, F., Mills, G.B., Overcoming implementation challenges of personalized cancer therapy. Nat. Rev. Clin. Oncol 9 (2012), 542–548.
93. [93] Saintigny, P., Burger, J.A., Recent advances in non-small cell lung cancer biology and clinical management. Discov. Med 13 (2012), 287–297.
94. [94] Curigliano, G., New drugs for breast cancer subtypes: targeting driver pathways to overcome resistance. Cancer Treat. Rev 38 (2012), 303–310.
95. [95] Van Cutsem, E., Lenz, H.J., Kohne, C.H., Heinemann, V., Tejpar, S., Melezinek, I., et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J. Clin. Oncol 33 (2015), 692–700.
96. [96] Sonkin, D., Hassan, M., Murphy, D.J., Tatarinova, T.V., Tumor suppressors status in cancer cell line Encyclopedia. Mol. Oncol 7 (2013), 791–798.
97. [97] Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483 (2012), 603–607.
98. [98] McMillin, D.W., Negri, J.M., Mitsiades, C.S., The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat. Rev. Drug Discov 12 (2013), 217–228.
99. [99] Unger, F.T., Witte, I., David, K.A., Prediction of individual response to anticancer therapy: historical and future perspectives. Cell Mol. Life Sci 72 (2015), 729–757.
100. [100] Roth, M.D., Harui, A., Human tumor infiltrating lymphocytes cooperatively regulate prostate tumor growth in a humanized mouse model. J. Immunother. Cancer, 3, 2015, 12.
101. [101] Morton, J.J., Bird, G., Keysar, S.B., Astling, D.P., Lyons, T.R., Anderson, R.T., et al. XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. Oncogene, 2015, 10.1038/onc.2015.94.
102. [102] Hovelson, D.H., McDaniel, A.S., Cani, A.K., Johnson, B., Rhodes, K., Williams, P.D., et al. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia 17 (2015), 385–399.
103. [103] Holohan, C., Van Schaeybroeck, S., Longley, D.B., Johnston, P.G., Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13 (2013), 714–726.
104. [104] Msaouel, P., Galeas, J.N., Boiles, A.R., Ruiz, R.R., Koutsilieris, M., Targeting the bone microenvironment in metastatic castration-resistant prostate cancer. Curr. Drug Targets, 2015.
105. [105] Alspach, E., Flanagan, K.C., Luo, X., Ruhland, M.K., Huang, H., Pazolli, E., et al. p38MAPK plays a crucial role in stromal-mediated tumorigenesis. Cancer Discov 4 (2014), 716–729.
106. [106] Laberge, R.M., Sun, Y., Orjalo, A.V., Patil, C.K., Freund, A., Zhou, L., et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat. Cell Biol 17 (2015), 1049–1061.